Literature DB >> 16709830

Protein kinase C-theta-mediated signals enhance CD4+ T cell survival by up-regulating Bcl-xL.

Santhakumar Manicassamy1, Sonal Gupta, Zhaofeng Huang, Zuoming Sun.   

Abstract

Productive engagement of TCR results in delivering signals required for T cell proliferation as well as T cell survival. Blocking TCR-mediated survival signals, T cells undergo apoptosis instead of proliferation upon TCR stimulation. During the activation process, T cells produce IL-2, which acts as an extrinsic survival factor. In addition, TCR stimulation results in up-regulation of Bcl-xL to enhance T cell survival intrinsically. We show in this study that protein kinase C (PKC)-theta is required for enhancing the survival of activated CD4+ T cells by up-regulating Bcl-xL. In response to TCR stimulation, CD4+ PKC-theta-/- T cells failed to up-regulate Bcl-xL, and underwent accelerated apoptosis via a caspase- and mitochondria-dependent pathway. Similar to PKC-theta-deficient primary CD4+ T cells, small interfering RNA-mediated knockdown of PKC-theta in Jurkat cells also resulted in apoptosis upon TCR stimulation. Forced expression of Bcl-xL was sufficient to inhibit apoptosis observed in PKC-theta knockdown cells. Furthermore, ectopic expression of PKC-theta stimulated a reporter gene driven by a mouse Bcl-xL promoter. Whereas an inactive form of PKC-theta or knockdown of endogenous PKC-theta led to inhibition of Bcl-xL reporter. PKC-theta-mediated activation of Bcl-xL reporter was inhibited by dominant-negative IkappaB kinase beta or dominant-negative AP-1. Thus, the PKC-theta-mediated signals may function not only in the initial activation of naive CD4+ T cells, but also in their survival during T cell activation by regulating Bcl-xL levels through NF-kappaB and AP-1 pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709830     DOI: 10.4049/jimmunol.176.11.6709

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  PKC-θ is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection.

Authors:  Myung-Ja Kwon; Ruiqing Wang; Jian Ma; Zuoming Sun
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-12       Impact factor: 2.895

Review 2.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

3.  Protein kinase C-θ inhibits inducible regulatory T cell differentiation via an AKT-Foxo1/3a-dependent pathway.

Authors:  Jian Ma; Yan Ding; Xianfeng Fang; Ruiqing Wang; Zuoming Sun
Journal:  J Immunol       Date:  2012-04-25       Impact factor: 5.422

4.  Protective Toxoplasma gondii-specific T-cell responses require T-cell-specific expression of protein kinase C-theta.

Authors:  Gopala Nishanth; Monika Sakowicz-Burkiewicz; Ulrike Händel; Stefanie Kliche; Xiaoqian Wang; Michael Naumann; Martina Deckert; Dirk Schlüter
Journal:  Infect Immun       Date:  2010-05-24       Impact factor: 3.441

5.  Protein kinase C-theta is required for efficient positive selection.

Authors:  Sharon Celeste Morley; K Scott Weber; Henry Kao; Paul M Allen
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

Review 6.  The yin and yang of protein kinase C-theta (PKCθ): a novel drug target for selective immunosuppression.

Authors:  Elizabeth Yan Zhang; Kok-Fai Kong; Amnon Altman
Journal:  Adv Pharmacol       Date:  2013

Review 7.  The emerging role of protein kinase Cθ in cytoskeletal signaling.

Authors:  Izabela Michalczyk; Aleksander F Sikorski; Leszek Kotula; Richard P Junghans; Patrycja M Dubielecka
Journal:  J Leukoc Biol       Date:  2012-11-27       Impact factor: 4.962

8.  A critical role for protein kinase C-theta-mediated T cell survival in cardiac allograft rejection.

Authors:  Santhakumar Manicassamy; Dengping Yin; Zheng Zhang; Luciana L Molinero; Marisa-Luisa Alegre; Zuoming Sun
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta.

Authors:  Wing-Yiu Lee; Peter Hampson; Lydia Coulthard; Farrah Ali; Mike Salmon; Janet M Lord; Dagmar Scheel-Toellner
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

10.  Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma.

Authors:  Tomoyuki Tano; Masato Okamoto; Shin Kan; Koh-Ichi Nakashiro; Shigetaka Shimodaira; Shigeo Koido; Sadamu Homma; Mitsunobu Sato; Tomonobu Fujita; Yutaka Kawakami; Hiroyuki Hamakawa
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.